Penumbra's STORM-PE Trial Shows CAVT with Anticoagulation Significantly Improves Outcomes in Pulmonary Embolism
Reuters
Nov 04, 2025
Penumbra's STORM-PE Trial Shows CAVT with Anticoagulation Significantly Improves Outcomes in Pulmonary Embolism
Penumbra, Inc. has announced additional results from the STORM-PE randomized controlled trial evaluating the use of computer assisted vacuum thrombectomy (CAVT™) with anticoagulation in patients with acute intermediate-high risk pulmonary embolism (PE). According to the company, the STORM-PE trial demonstrated that CAVT combined with anticoagulation resulted in significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone. These results were presented at the Vascular Interventional Advances (VIVA) 2025 Conference and published in the journal Circulation. The findings suggest that CAVT with anticoagulation may offer superior efficacy over anticoagulation alone for this patient population.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Penumbra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF13383) on November 03, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.